Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy

References

• StovnerLHagenKJensenRThe global burden of headache: a documentation of headache prevalence and disability worldwideCephalalgia200727319321017381554
   PubMed Web of Science ®Google Scholar
• GBD 2016 Disease and Injury Incidence and Prevalence CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990– 2016: a systematic analysis for the Global Burden of Disease Study 2016Lancet2017390101001211125928919117
   PubMed Web of Science ®Google Scholar
• LindeMGustavssonAStovnerLJThe cost of headache disorders in Europe: the Eurolight projectEur J Neurol201219570371122136117
   PubMed Web of Science ®Google Scholar
• AntonaciFGhiottoNWuSPucciECostaARecent advances in migraine therapySpringerplus20165163727330903
   PubMedGoogle Scholar
• LiptonRBTracing transformation: chronic migraine classification, progression, and epidemiologyNeurology2009725 SupplS3S719188564
   PubMed Web of Science ®Google Scholar
• NegroARocchietti-MarchMFiorilloMMartellettiPChronic migraine: current concepts and ongoing treatmentsEur Rev Med Pharmacol Sci201115121401142022288302
   PubMed Web of Science ®Google Scholar
• NegroACurtoMLionettoLGuerzoniSPiniLAMartellettiPA critical evaluation on MOH current treatmentsCurr Treat Options Neurol20171993228808924
   PubMed Web of Science ®Google Scholar
• KashipazhaDGhadikolaeiHSSiavashiMLevetiracetam in compare to sodium valproate for prophylaxis in chronic migraine headache: a randomized double-blind clinical trialCurr Clin Pharmacol2017121555928356053
   PubMed Web of Science ®Google Scholar
• AssarzadeganFTabeshHHosseini-ZijoudSMComparing zonisamide with sodium valproate in the management of migraine headaches: double-blind randomized clinical trial of efficacy and safetyIran Red Crescent Med J2016189e2376828144450
   PubMed Web of Science ®Google Scholar
• DienerHCGendollaAFeuersengerATelmisartan in migraine prophylaxis: a randomized, placebo-controlled trialCephalalgia200929992192719250283
   PubMed Web of Science ®Google Scholar
• StovnerLJLindeMGravdahlGBA comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over studyCephalalgia201434752353224335848
   PubMed Web of Science ®Google Scholar
• HesamiOSistanizadMAsadollahzadeEJohariMSBeladi-MoghadamNMazhabdar-GhashghaiHComparing the effects of atorvastatin with sodium valproate (divalproex) on frequency and intensity of frequent migraine headaches: a double-blind randomized controlled studyClin Neuropharmacol2018413949729746282
   PubMed Web of Science ®Google Scholar
• Ebrahimi-MonfaredMSharafkhahMAbdolrazaghnejadAMoham-madbeigiAFarajiFUse of melatonin versus valproic acid in prophylaxis of migraine patients: a double-blind randomized clinical trialRestor Neurol Neurosci201735438539328800342
   PubMed Web of Science ®Google Scholar
• ChoSJSongTJChuMKTreatment update of chronic migraineCurr Pain Headache Rep20172162628424953
   PubMed Web of Science ®Google Scholar
• NegroAD’AlonzoLMartellettiPChronic migraine: comorbidities, risk factors, and rehabilitationIntern Emerg Med20105Suppl 1S13S1920865469
   PubMed Web of Science ®Google Scholar
• LionettoLBorroMCurtoMChoosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerationsExpert Opin Drug Metab Toxicol201612439940626878379
   PubMed Web of Science ®Google Scholar
• LiptonRBBigalMEDiamondMAMPP Advisory GroupMigraine prevalence, disease burden, and the need for preventive therapyNeurology200768534334917261680
   PubMed Web of Science ®Google Scholar
• HeppZDodickDWVaronSFGillardPHansenRNDevineEBAdherence to oral migraine-preventive medications among patients with chronic migraineCephalalgia201535647848825164920
   PubMed Web of Science ®Google Scholar
• BigalMESerranoDReedMLiptonRBChronic migraine in the population: burden, diagnosis, and satisfaction with treatmentNeurology200871855956618711108
   PubMed Web of Science ®Google Scholar
• BlumenfeldAMBloudekLMBeckerWJPatterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second International burden of migraine study (IBMS-II)Headache201353464465523458496
   PubMed Web of Science ®Google Scholar
• HeppZBloudekLMVaronSFSystematic review of migraine prophylaxis adherence and persistenceJ Manag Care Pharm2014201223324372457
   PubMed Web of Science ®Google Scholar
• RamseyRRRyanJLHersheyADPowersSWAylwardBSHommelKATreatment adherence in patients with headache: a systematic reviewHeadache201454579581624750017
   PubMed Web of Science ®Google Scholar
• DekkerFKnuistingh NevenAAndriesseBProphylactic treatment of migraine; the patient’s view, a qualitative studyBMC Fam Pract20121311322405186
   PubMed Web of Science ®Google Scholar
• RozenTDMigraine prevention: what patients want from medication and their Physicians (a headache specialty clinic perspective)Headache200646575075316643577
   PubMed Web of Science ®Google Scholar
• PeresMFPSilbersteinSMoreiraFPatients’ preference for migraine preventive therapyHeadache200747454054517445103
   PubMed Web of Science ®Google Scholar
• KowacsPAPiovesanEJTepperSJRejection and acceptance of possible side effects of migraine prophylactic drugsHeadache20094971022102719438733
   PubMed Web of Science ®Google Scholar
• SmeltAFHEijsengaSJAssendelftWJJBlomJWAcceptance of preventive treatment in migraine patients: results of a surveyEur J Gen Pract201218314314822954193
   PubMed Web of Science ®Google Scholar
• GoadsbyPJThe vascular theory of migraine – a great story wrecked by the factsBrain2009132Pt 16719098031
   PubMed Web of Science ®Google Scholar
• PietrobonDMoskowitzMAPathophysiology of migraineAnnu Rev Physiol201375136539123190076
   PubMed Web of Science ®Google Scholar
• MesslingerKMigraine: where and how does the pain originate?Exp Brain Res2009196117919319288089
   PubMed Web of Science ®Google Scholar
• RaddantACRussoAFCalcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulationExpert Rev Mol Med201113e3622123247
   PubMed Web of Science ®Google Scholar
• EdvinssonLHaanesKAWarfvingeKKrauseDNCGRP as the target of new migraine therapies – successful translation from bench to clinicNat Rev Neurol201814633835029691490
   PubMed Web of Science ®Google Scholar
• RussellFAKingRSmillieSJKodjiXBrainSDCalcitonin gene-related peptide: physiology and pathophysiologyPhysiol Rev20149441099114225287861
   PubMed Web of Science ®Google Scholar
• MulderryPKGhateiMABishopAEAllenYSPolakJMBloomSRDistribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the ratRegul Pept19851221331433877953
   PubMedGoogle Scholar
• EftekhariSSalvatoreCACalamariAKaneSATajtiJEdvinssonLDifferential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglionNeuroscience2010169268369620472035
   PubMed Web of Science ®Google Scholar
• EftekhariSSalvatoreCAJohanssonSChenTBZengZEdvinssonLLocalization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrierBrain Res201516009310925463029
   PubMed Web of Science ®Google Scholar
• WalkerCSHayDLCGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?Br J Pharmacol201317071293130723425327
   PubMed Web of Science ®Google Scholar
• GallaiVSarchielliPFloridiAVasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictallyCephalalgia19951553843908536297
   PubMed Web of Science ®Google Scholar
• Cernuda-MorollónELarrosaDRamónCVegaJMartínez-CamblorPPascualJInterictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraineNeurology201381141191119623975872
   PubMed Web of Science ®Google Scholar
• GoadsbyPJEdvinssonLEkmanRVasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnn Neurol19902821831871699472
   PubMed Web of Science ®Google Scholar
• GoadsbyPJEdvinssonLThe trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnn Neurol199333148568388188
   PubMed Web of Science ®Google Scholar
• SarchielliPAlbertiACodiniMFloridiAGallaiVNitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacksCephalalgia2000201090791811304026
   PubMed Web of Science ®Google Scholar
• JuhaszGZsombokTJakabBNemethJSzolcsanyiJBagdyGSumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attackCephalalgia200525317918315689192
   PubMed Web of Science ®Google Scholar
• LassenLHJacobsenVBHaderslevPAInvolvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patientsJ Headache Pain20089315115718437288
   PubMed Web of Science ®Google Scholar
• HansenJMHaugeAWOlesenJAshinaMCalcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with auraCephalalgia201030101179118620855363
   PubMed Web of Science ®Google Scholar
• AsgharMSHansenAEAminFMEvidence for a vascular factor in migraineAnn Neurol201169463564521416486
   PubMed Web of Science ®Google Scholar
• RecoberAKuburasAZhangZWemmieJAAndersonMGRussoAFRole of calcitonin gene-related peptide in light-aversive behavior: implications for migraineJ Neurosci200929278798880419587287
   PubMed Web of Science ®Google Scholar
• OlesenJDienerHCHusstedtIWBIBN 4096 BS Clinical Proof of Concept Study GroupCalcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraineN Engl J Med2004350111104111015014183
   PubMed Web of Science ®Google Scholar
• HoTWFerrariMDDodickDWEfficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trialLancet200837296562115212319036425
   PubMed Web of Science ®Google Scholar
• ConnorKMShapiroREDienerHCRandomized, controlled trial of telcagepant for the acute treatment of migraineNeurology2009731297097719770473
   PubMed Web of Science ®Google Scholar
• VossTLiptonRBDodickDWA phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraineCephalalgia201636988789827269043
   PubMed Web of Science ®Google Scholar
• HewittDJAuroraSKDodickDWRandomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraineCephalalgia201131671272221383045
   PubMed Web of Science ®Google Scholar
• MarcusRGoadsbyPJDodickDStockDManosGFischerTZBMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trialCephalalgia201434211412523965396
   PubMed Web of Science ®Google Scholar
• SunHDodickDWSilbersteinSSafety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trialLancet Neurol201615438239026879279
   PubMed Web of Science ®Google Scholar
• TepperSAshinaMReuterUSafety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trialLancet Neurol201716642543428460892
   PubMed Web of Science ®Google Scholar
• GoadsbyPJReuterUHallströmYA controlled trial of Erenumab for episodic migraineN Engl J Med2017377222123213229171821
   PubMed Web of Science ®Google Scholar
• DodickDWGoadsbyPJSilbersteinSDALD403 study investigatorsSafety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trialLancet Neurol201413111100110725297013
   PubMed Web of Science ®Google Scholar
• BigalMEDodickDWRapoportAMSafety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2B studyLancet Neurol201514111081109026432182
   PubMed Web of Science ®Google Scholar
• BigalMEDodickDWKrymchantowskiAVTEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time pointsNeurology2016871414827281531
   PubMed Web of Science ®Google Scholar
• SilbersteinSDDodickDWBigalMEFremanezumab for the preventive treatment of chronic migraineN Engl J Med2017377222113212229171818
   PubMed Web of Science ®Google Scholar
• DodickDWSilbersteinSDBigalMEEffect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trialJAMA2018319191999200829800211
   PubMed Web of Science ®Google Scholar
• DodickDWGoadsbyPJSpieringsELHSchererJCSweeneySPGrayzelDSSafety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled studyLancet Neurol201413988589225127173
   PubMed Web of Science ®Google Scholar
• SkljarevskiVOakesTMZhangQEffect of different doses of Galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trialJAMA Neurol201875218719329255900
   PubMed Web of Science ®Google Scholar
• StaufferVLDodickDZhangMCarterJNAilaniJConleyRREvaluation of Galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trialJAMA Neurol20187591080108829813147
   PubMed Web of Science ®Google Scholar
• SkljarevskiVMatharuMMillenBAOssipovMHKimBKYangJYEfficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trialCephalalgia20183881442145429848108
   PubMed Web of Science ®Google Scholar
• BenschopRJCollinsECDarlingRJDevelopment of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related painOsteoarthritis Cartilage201422457858524508775
   PubMed Web of Science ®Google Scholar
• BuntinxLVermeerschSde HoonJDevelopment of anti-migraine therapeutics using the capsaicin-induced dermal blood flow modelBr J Clin Pharmacol2015805992100026114340
   PubMed Web of Science ®Google Scholar
• Van der SchuerenBJRogiersAVanmolkotFHCalcitonin gene-related peptide 8–37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic modelJ Pharmacol Exp Ther2008325124825518216286
   PubMed Web of Science ®Google Scholar
• HolzerPLocal effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptidesNeuroscience19882437397683288903
   PubMed Web of Science ®Google Scholar
• Van der SchuerenBJde HoonJNVanmolkotFHReproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imagingBr J Clin Pharmacol200764558059017578484
   PubMed Web of Science ®Google Scholar
• VermeerschSBenschopRJVan HeckenATranslational pharmacodynamics of calcitonin gene-related peptide monoclonal antibody LY2951742 in a capsaicin-induced dermal blood flow modelJ Pharmacol Exp Ther2015354335035726116630
   PubMed Web of Science ®Google Scholar
• MonteithDCollinsECVandermeulenCSafety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (galcanezumab) in healthy volunteersFront Pharmacol2017874029089894
   PubMed Web of Science ®Google Scholar
• Galcanezumab2006 Available from: http://www.ncbi.nlm.nih.gov/pubmed/30372007Accessed November 9, 2018
   Google Scholar
• OakesTMMSkljarevskiVZhangQSafety of galcanezumab in patients with episodic migraine: a randomized placebo-controlled dose-ranging phase 2B studyCephalalgia20183861015102529310444
   PubMed Web of Science ®Google Scholar
• ZhouHMascelliMAMechanisms of monoclonal antibody-drug interactionsAnnu Rev Pharmacol Toxicol201151135937220936946
   PubMed Web of Science ®Google Scholar
• StaufferVLSidesRLanteri-MinetMComparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studiesPatient Prefer Adherence2018121785179530271122
   PubMed Web of Science ®Google Scholar
• Tfelt-HansenPSite of effect of LY2951742 for migraine prophylaxisLancet Neurol2015141313225496894
   PubMed Web of Science ®Google Scholar
• DodickDWGoadsbyPJSpieringsELSchererJCSweeneySPGrayzelDSSite of effect of LY2951742 for migraine prophylaxis – authors’ replyLancet Neurol2015141323325496895
   PubMed Web of Science ®Google Scholar
• SchankinCJManiyarFHSeoYIctal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraineBrain201613971994200127234268
   PubMed Web of Science ®Google Scholar
• PrestonJEJoan AbbottNBegleyDJTranscytosis of macromolecules at the blood-brain barrierAdv Pharmacol20147114716325307216
   PubMedGoogle Scholar
• KarasekCOjalaEAllisonDCharacterization of the intrinsic binding features of three anti-CGRP therapeutic antibodies effective in preventing migraine: a comparative pre-clinical case study of ALD403, LY-2951742, TEV-4812558th Annual Scientific Meeting of the American Headache SocietySan Diego, CA2016251
   Google Scholar
• KhanSOlesenAAshinaMCgrpAMCGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical dataCephalalgia2017200333102417741297
   Google Scholar
• MitsikostasDDReuterUCalcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studiesCurr Opin Neurol201730327228028240610
   PubMed Web of Science ®Google Scholar
• RosenNPearlmanERuffDDayKJim NagyA100% response rate to galcanezumab in patients with episodic migraine: a post hoc analysis of the results from phase 3, randomized, double-blind, placebo-controlled EVOLVE-1 and EVOLVE-2 studiesHeadache: J Head Face Pain201858913471357
   PubMed Web of Science ®Google Scholar
• DetkeHCGoadsbyPJWangSFriedmanDISelzlerKJAuroraSKGalcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN studyNeurology20189124e2211e222130446596
   PubMed Web of Science ®Google Scholar
• CamporealeAKudrowDSidesRA phase 3, long-term, open-label safety study of Galcanezumab in patients with migraineBMC Neurol201818118830413151
   PubMed Web of Science ®Google Scholar
• FordJHFosterSAStaufferVLAuroraSKVersijptJSatisfaction P. Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine2018201824132424
   Google Scholar
• FörderreutherSZhangQStaufferVLAuroraSKLáinezMJAPreventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and regain studiesJ Headache Pain201819112130594122
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyAAN 2018: Lilly’s galcanezumab significantly reduced monthly migraine headache days in patients with migraine who previously failed to respond to multiple preventive therapies201828587 Available from: https://www.prnewswire.com/news-releases/aan-2018-lillys-galcanezumab-significantly-reduced-monthly-migraine-headache-days-in-patients-with-migraine-who-previously-failed-to-respond-to-multiple-preventive-therapies-300634848.htmlAccessed February 22, 2019
   Google Scholar
• NicholsRDotyESaccoSRuffDPearlmanEAuroraSKAnalysis of initial nonresponders to Galcanezumab in patients with episodic or chronic migraine: results from the EVOLVE-1, EVOLVE-2, and regain randomized, double-blind, placebo-controlled studiesHeadache201959219220430462830
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyA Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine – Full Text View – ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT03559257Accessed August 25, 2018
   Google Scholar
• Eli Lilly and CompanyA Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine – Full Text View – ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT03432286Accessed August 25, 2018
   Google Scholar
• Eli Lilly and CompanyA Study of LY2951742 in Participants With Episodic Cluster Headache – Full Text View – ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT02397473Accessed August 25, 2018
   Google Scholar
• Eli Lilly and CompanyA Study of LY2951742 in Participants With Chronic Cluster Headache – Full Text View – ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT02438826Accessed August 25, 2018
   Google Scholar
• Eli Lilly and CompanyA Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache – Full Text View – ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT02797951Accessed August 25, 2018
   Google Scholar
• AyerDWSkljarevskiVFordJHNyhuisAWLiptonRBAuroraSKMeasures of functioning in patients with episodic migraine: findings from a double-blind, randomized, placebo-controlled phase 2B trial with GalcanezumabHeadache20185881225123530106172
   PubMed Web of Science ®Google Scholar
• SengEKRainsJANicholsonRALiptonRBImproving medication adherence in migraine treatmentCurr Pain Headache Rep20151962426040703
   PubMed Web of Science ®Google Scholar
• DepreCAntalikLStarlingAA randomized, double-blind, placebo-controlled study to evaluate the effect of Erenumab on exercise time during a treadmill test in patients with stable anginaHeadache201858571572329878340
   PubMed Web of Science ®Google Scholar